Samsung Bioepis “Keytruda similar met primary indicators in phase 1 and 3 clinical trials”
⚡ Quick Summary
(Seoul = Yonhap News) Reporter Shin Seon-mi = Samsung Bioepis is conducting a global clinical trial of a biosimilar of the immunotherapy drug Keytruda (ingredient name: pembrolizumab, project name: SB27)...
📰 Related Articles
To compensate for losses from the maximum oil price system, a fierce battle over the key ‘cost range’ begins
Khan
National Tax Service, National Agricultural Cooperative Federation special tax investigation... Over 100 people deployed
Khan
HD Korea Shipbuilding & Marine Engineering succeeds in localizing key equipment for LNG propulsion ships
Khan
KB Financial Group closes 7 trillion won in win-win financial funds this year
KhanIran: "There are no working-level talks with the U.S. scheduled for this week"... Qatar talks denied
연합뉴스TV